171 related articles for article (PubMed ID: 32829304)
21. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
Sivaprasad S; Prevost AT; Vasconcelos JC; Riddell A; Murphy C; Kelly J; Bainbridge J; Tudor-Edwards R; Hopkins D; Hykin P;
Lancet; 2017 Jun; 389(10085):2193-2203. PubMed ID: 28494920
[TBL] [Abstract][Full Text] [Related]
22. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
23. Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study.
Busch C; Wakabayashi T; Sato T; Fukushima Y; Hara C; Shiraki N; Winegarner A; Nishida K; Sakaguchi H; Nishida K
Sci Rep; 2019 Feb; 9(1):1561. PubMed ID: 30733512
[TBL] [Abstract][Full Text] [Related]
24. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
[TBL] [Abstract][Full Text] [Related]
26. Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema.
Sugimoto M; Ichio A; Mochida D; Tenma Y; Miyata R; Matsubara H; Kondo M
Ophthalmol Retina; 2019 Dec; 3(12):1067-1075. PubMed ID: 31446029
[TBL] [Abstract][Full Text] [Related]
27. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
Blindbæk SL; Peto T; Grauslund J
Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
[TBL] [Abstract][Full Text] [Related]
28. LONGITUDINAL ANALYSIS OF DIABETIC CHOROIDOPATHY IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION USING WIDEFIELD SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY.
Russell JF; Zhou H; Shi Y; Shen M; Gregori G; Feuer WJ; Wang RK; Rosenfeld PJ
Retina; 2022 Mar; 42(3):417-425. PubMed ID: 34861657
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
Abd Elhamid AH; Mohamed AAEA; Khattab AM
BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
Wykoff CC; Shah C; Dhoot D; Coleman HR; Thompson D; Du W; Baker K; Vitti R; Berliner AJ; Metzig C; Saroj N
Ophthalmology; 2019 Aug; 126(8):1171-1180. PubMed ID: 30946887
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
34. Analysis of quantitative correlations between microaneurysm, ischaemic index and new vessels in ultrawide-field fluorescein angiography images using automated software.
Son G; Kim YJ; Sung YS; Park B; Kim JG
Br J Ophthalmol; 2019 Dec; 103(12):1759-1764. PubMed ID: 30872285
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal Quantitative Ultrawide-field Fluorescein Angiography Dynamics in the RUBY Diabetic Macular Edema Study.
Sarici K; Yordi S; Martin A; Lunasco L; Mugnaini C; Chu K; Moini H; Vitti R; Srivastava SK; Ehlers JP
Ophthalmol Retina; 2023 Jun; 7(6):543-552. PubMed ID: 36736895
[TBL] [Abstract][Full Text] [Related]
36. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial.
Kanar HS; Arsan A; Altun A; Akı SF; Hacısalihoglu A
Indian J Ophthalmol; 2020 Jan; 68(1):145-151. PubMed ID: 31856493
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
39. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
Ozsaygili C; Duru N
Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naïve patients.
Tao Y; Jiang P; Liu M; Liu Y; Song L; Wang H
J Int Med Res; 2021 Jan; 49(1):300060520985369. PubMed ID: 33499698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
